BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September

Day

• 1
• 2
• 3
• 4
• 5
• 8
• 9
• 10

• Press Releases

  Roche receives CE mark for Contivue, its Port Delivery Platform containing Susvimo, for neovascular age-related macular degeneration (nAMD)

  September 4, 2025

   · 

  10 min read
• Press Releases

  ALK expands the Executive Leadership Team to include key commercial regions

  September 4, 2025

   · 

  3 min read
• Press Releases

  Skye’s CB1 Inhibitor, Nimacimab, Demonstrates Superior Weight Loss and Differentiated Mechanisms from Monlunabant, and Continues to Show Enhanced Combination with Tirzepatide with Durable Post-Treatment Weight Maintenance in DIO Model

  September 4, 2025

   · 

  7 min read
• Press Releases

  SPEAR Study Group to Present its Recommended Long COVID Antibody Study Design Featuring Invivyd’s VYD2311 At RECOVER-TLC Workshop September 9-10, 2025

  September 4, 2025

   · 

  8 min read
• Press Releases

  Agios Provides Update on U.S. PDUFA Goal Date for PYRUKYND® (mitapivat) in Thalassemia

  September 4, 2025

   · 

  9 min read
• Press Releases

  Climb Bio to Host Webcast Highlighting CLYM116 and the IgA Nephropathy (IgAN) Opportunity on September 29, 2025

  September 4, 2025

   · 

  5 min read
• Press Releases

  C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration

  September 4, 2025

   · 

  4 min read
• Press Releases

  Aquestive Therapeutics Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for Anaphylm™

  September 4, 2025

   · 

  9 min read
• Press Releases

  Hinge Bio Expands Leadership Team to Drive Clinical Development of GEM-DIMER™ Programs and Announces Publication in Scientific Reports

  September 4, 2025

   · 

  6 min read
• Press Releases

  Walden Biosciences Announces Key Initiatives to Advance Clinical Pipeline and Support Phase 2 Program for WAL0921 in Rare Kidney Diseases

  September 4, 2025

   · 

  6 min read